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A BS TR AC T
BACKGROUND
The results of meta-analyses examining the relationship between vitamin D supple-
mentation and fracture reduction have been inconsistent.
METHODS
We pooled participant-level data from 11 double-blind, randomized, controlled trials 
of oral vitamin D supplementation (daily, weekly, or every 4 months), with or without 
calcium, as compared with placebo or calcium alone in persons 65 years of age or 
older. Primary end points were the incidence of hip and any nonvertebral fractures 
according to Cox regression analyses, with adjustment for age group, sex, type of 
dwelling, and study. Our primary aim was to compare data from quartiles of ac-
tual intake of vitamin D (including each individual participant’s adherence to the 
treatment and supplement use outside the study protocol) in the treatment groups 
of all trials with data from the control groups.
RESULTS
We included 31,022 persons (mean age, 76 years; 91% women) with 1111 incident hip 
fractures and 3770 nonvertebral fractures. Participants who were randomly assigned 
to receive vitamin D, as compared with those assigned to control groups, had a 
nonsignificant 10% reduction in the risk of hip fracture (hazard ratio, 0.90; 95% 
confidence interval [CI], 0.80 to 1.01) and a 7% reduction in the risk of nonvertebral 
fracture (hazard ratio, 0.93; 95% CI, 0.87 to 0.99). By quartiles of actual intake, 
reduction in the risk of fracture was shown only at the highest intake level (median, 
800 IU daily; range, 792 to 2000), with a 30% reduction in the risk of hip fracture 
(hazard ratio, 0.70; 95% CI, 0.58 to 0.86) and a 14% reduction in the risk of any non-
vertebral fracture (hazard ratio, 0.86; 95% CI, 0.76 to 0.96). Benefits at the highest 
level of vitamin D intake were fairly consistent across subgroups defined by age group, 
type of dwelling, baseline 25-hydroxyvitamin D level, and additional calcium intake.
CONCLUSIONS
High-dose vitamin D supplementation (≥800 IU daily) was somewhat favorable in 
the prevention of hip fracture and any nonvertebral fracture in persons 65 years of 
age or older. (Funded by the Swiss National Foundations and others.)
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A pproximately 75% of fractures oc-cur in people 65 years of age or older.1 By 2050, the worldwide incidence of hip frac-
tures is expected to increase by 240% among wom-
en and 310% among men.2
One strategy to prevent fractures in this popu-
lation might be universal vitamin D supplemen-
tation. However, the results of several study level 
meta-analyses and one pooled participant- 
level analysis do not agree. Although one trial-
level meta-analysis of double-blind, randomized, 
controlled trials suggested an 18% reduction in 
the incidence of hip fracture and a 20% reduction 
in the incidence of any nonvertebral fracture at a 
received dose of no less than 482 IU of vitamin D 
per day,3 three study-level meta-analyses4-6 and 
one pooled analysis of participant-level data7 
from open-design and blinded trials suggested 
that vitamin D may have no effect on total frac-
tures4 or may reduce hip fracture by 7 to 16%, if 
combined with calcium supplementation, regard-
less of the dose of vitamin D.4-7 The discordant 
findings may be explained, in part, by differences 
in the criteria for including trials in the analyses, 
with respect to blinding, vitamin D formulation 
(oral vs. injectable), or accommodations for non-
adherence. Our analysis was designed to esti-
mate the effects of vitamin D supplementation 
according to the actual intake of each partici-
pant, rather than simply the dose to which the 
participant was randomly assigned.
ME THODS
POOLED STUDIES
We attempted to identify all double-blind, random-
ized, controlled trials involving persons 65 years 
of age or older that evaluated oral vitamin D sup-
plementation, alone or in combination with calci-
um, as compared with a control (placebo or calci-
um alone); that included data on low-trauma 
fractures; and that were published on or before 
August 31, 2011. We conducted searches of Med-
line, the Cochrane Central Register of Controlled 
Trials, and Embase. Of 14 qualifying trials, 2 were 
unavailable (lost files), both of which showed a 
significant reduction in fracture risk at a treat-
ment dose that was equivalent to 800 IU of vita-
min D per day.8,9
We included 12 studies (with a total of 33,277 
participants) and received the source data for 
30,011 participants 65 years of age or older from 
11 trials, including type and date of fracture and 
dates of study entry and exit. For the 1 study of 
the 12 (with 3266 participants) for which events 
were identified by month,10 we made the assump-
tion that events had occurred in mid-month. 
One study (with 2255 participants) provided the 
dose once yearly11; in the other 11 studies (with 
31,022 participants), the dose of vitamin D was 
given daily,10,12-19 weekly,20 or every 4 months.21 
The RECORD (Randomised Evaluation of Calcium 
or Vitamin D) trial, which had a factorial design, 
was split into study A (vitamin D vs. placebo) and 
study B (vitamin D plus calcium vs. calcium alone) 
trials.16 The work was done collegially with no 
limitations on confidentiality, except the removal 
of patient identifiers. All the included studies re-
quired that participants provide written informed 
consent.
VARIABLES
Because adherence to the study treatment was 
documented differently in the published trials, 
we incorporated data on adherence according to 
a predefined protocol. For 7 trials, data on adher-
ence were available at the participant level. For the 
4 trials without participant-level reports of ad-
herence, we applied the mean value for adher-
ence (80%14,19,21 or 95%15) of that trial to the in-
dividual participant doses. Vitamin D supple- 
mentation outside the study protocol was per-
mitted in 5 of 11 trials,14-17,21 3 of which provided 
participant-level data that we incorporated in the 
assessment of actual intake in the primary analy-
sis.15-17 The other 2 trials either allowed up to 
200 IU14 of vitamin D per day or included per-
sons if they had a vitamin D intake of less than 
400 IU per day,21 without providing participant-
level information on additional intake. Data on sex 
and type of dwelling were available for all partici-
pants from all 12 studies. For 1 of the 12 stud-
ies,10 we did not have participant-level data on 
age, so we applied the cohort average to each par-
ticipant. Fracture events in all trials were verified 
by a review of medical records. We excluded ver-
tebral fractures because they were not document-
ed systematically in any of the trials.
PRIMARY ANALYSES
The primary end points were the risks of hip 
fracture and any nonvertebral fracture. The pri-
mary analyses compared the actual intake of vi-
tamin D supplementation, in quartiles, between 
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treated participants and controls (with actual in-
take calculated as the assigned treatment dose plus 
any additional supplemental dose, with adjust-
ment for adherence). In a sensitivity analysis, we 
excluded any additional supplemental dose outside 
the study protocol from the calculation of actual 
intake.
To establish a bridge to earlier meta-analyses 
and explain the additional information gained by 
the comparison of actual-intake amounts, we in-
cluded two additional analyses: an intention-to-
treat analysis that compared participants who had 
been randomly assigned to receive vitamin D or 
a control, and an analysis according to treatment 
dose that maintained the assigned randomization 
status (vitamin D vs. control) and the assigned 
treatment dose (≤400 IU per day vs. >400 IU per 
day). All analyses were controlled for study, sex, 
age group, and type of dwelling.
INTERNAL VALIDATION ANALYSIS
We performed an internal validation study to com-
pare the highest quartile of actual intake of vita-
min D with the lowest quartile, regardless of the 
randomized study-group assignment, including 
controls. Furthermore, with available baseline mea-
surements of 25-hydroxyvitamin D from a subset 
of 4383 participants, we performed a threshold 
assessment of the association between the base-
line quartile of 25-hydroxyvitamin D level and 
the prospective risk of hip fracture or any non-
vertebral fracture, independently of study group, 
age group, sex, type of dwelling, and study.
SENSITIVITY ANALYSES
In sensitivity analyses, we included 1 additional 
trial, by Sanders et al.,11 because it used a different 
treatment regimen, consisting of an annual high 
dose (500,000 IU) of vitamin D, and we added 
100 IU of vitamin D to the actual-intake amount 
for participants in the 2 trials in which a small 
dose of additional vitamin D was allowed but not 
documented.14,21 To extend our participant-level 
data to the 2 randomized, controlled trials (by 
Chapuy et al.9 and Trivedi et al.8) for which the 
source data were not available, we performed a 
trial-level meta-analysis that combined our pooled 
findings from the 11 randomized, controlled tri-
als with the trial-level findings of these 2 trials in 
a random-effects meta-analysis.
SUBGROUP ANALYSES
In predefined subgroup analyses we assessed the 
effect of actual intake of vitamin D according to 
age group (younger than 75 years, 75 to 84 years, 
or 85 years or older), type of dwelling (community 
dwelling vs. institution), baseline level of 25- 
hydroxyvitamin D (<30 nmol per liter vs. ≥30 nmol 
per liter), and additional dose of a calcium sup-
plement in the treatment group (<1000 mg per day 
vs. ≥1000 mg per day).
STATISTICAL ANALYSIS
After establishing homogeneity among the 11 in-
dividual trials for both fracture end points over-
all and at the actual-intake quartile level, we 
pooled the individual participant-level data and 
used Cox proportional-hazards regression analy-
sis to assess the incidence of hip fracture or any 
nonvertebral fracture. For the primary analyses, 
we performed only one analysis for hip fracture 
and one analysis for nonvertebral fracture in 
which we compared all quartiles of actual intake 
to the control group, and it was our a priori ex-
pectation that the effect would be greatest at the 
highest dose. In the nonprimary analyses, because 
of the potential for false positive results due to 
multiple testing, we used a P value of 0.0125 to 
indicate significance. Since four subgroups were 
considered for each of two types of fracture out-
come, an interaction term for the highest actual 
intake level of vitamin D and each subgroup was 
added to the model, and a Bonferroni-adjusted 
P value of less than 0.00625 was required for sig-
nificance.
All analyses were adjusted for study, age 
group, sex, and type of dwelling; however, the 
analyses were not adjusted for calcium supple-
mentation, owing to colinearity between doses 
of vitamin D and calcium supplementation. All 
reported P values are two-sided, and the propor-
tional-hazards assumptions were satisfied for 
the primary analyses for both hip fracture and 
any nonvertebral fracture. Additional frailty anal-
yses22 were carried out to ensure that the results 
were robust with respect to the allowance speci-
fied for correlation within the study. The results 
of these analyses are not reported, since they 
remained consistent and significant. Analyses 
were conducted with SAS software, version 9.2 
(SAS Institute).
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R ESULT S
CHARACTERISTICS OF THE PARTICIPANTS
The clinical characteristics of 31,022 partici-
pants from 11 trials are shown in Table 1. Of 
4383 participants with baseline measurements 
of 25-hydroxyvitamin D, 24% had levels of less 
than 30 nmol per liter, 62% had levels of less 
than 50 nmol per liter, and 88% had levels of 
less than 75 nmol per liter. Appendix 1 in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org, shows the as-
signed treatment doses and actual-intake amounts 
in each trial.
PRIMARY ANALYSES
The intention-to-treat analysis showed a nonsig-
nificant 10% reduction in the risk of hip fracture 
(hazard ratio, 0.90; 95% confidence interval [CI], 
0.80 to 1.01), which did not differ according to 
assigned treatment dose. On the basis of our pri-
mary comparison of actual intake, however, there 
was a significant 30% reduction in the incidence 
of hip fracture at the highest actual-intake level 
(792 to 2000 IU per day) in treated participants, 
as compared with controls (Table 2), with a sim-
ilar finding for the adherence-adjusted dose, which 
did not include supplements outside the study pro-
tocol (29% reduction). Notably, there was no re-
duction in the risk of hip fracture at any actual-
intake level lower than 792 IU per day.
In the internal validation analysis, regardless of 
study assignment, the reduction in the risk of hip 
fracture was 30% and was significant at the high-
est actual-intake level (792 to 2000 IU per day), as 
compared with the lowest actual-intake level (0 to 
360 IU per day), suggesting a dose–response rela-
tionship. Such a relationship was also suggested by 
the threshold assessment of hip-fracture risk ac-
cording to quartile of baseline 25-hydroxyvitamin 
D level in the 4383 participants for whom serum 
measurements were available (Fig. 1A).
The intention-to-treat analysis showed a 7% 
overall reduction in the risk of nonvertebral frac-
Table 1. Baseline Characteristics of the Study Populations in 11 Double-Blind, Randomized, Controlled Trials, According to Quartile 
of Actual Intake of Vitamin D among Treated Participants, as Compared with Controls.*
Variable
Control Group
(N = 15,495)
Treatment-Group Quartile
(N = 15,527)
0–360 IU/day
(N = 3935)
361–637 IU/day
(N = 3836)
638–791 IU/day
(N = 3790)
792–2000 IU/day
(N = 3966)
Median dose — IU/day 340 547 693 800
Age
Mean — yr 76.4±7.5 75.2±6.4 72.5±6.1 78.0±8.8 79.8±6.2
65–74 yr — % 48.5 53.0 72.0 43.9 25.7
75–84 yr — % 38.7 38.0 22.2 29.0 65.6
≥85 yr — % 12.8 9.0 5.8 27.1 8.7
Female sex — no. (%) 14,082 (90.9) 3510 (89.2) 3696 (96.4) 3216 (84.9) 3670 (92.5)
Living in institution — no. (%) 4,760 (30.7) 573 (14.6) 380 (9.9) 1970 (52.0) 1863 (47.0)
Supplement
Vitamin D, actual intake — IU/day 100±160 290±98 496±81 692±41 846±180
Calcium, actual intake — mg/day 84±258 396±393 697±282 403±436 830±460
25-Hydroxyvitamin D level
No. of participants 2220 440 679 632 412
Mean value — nmol/liter 47±24 41±24 48±21 54±29 43±20
Pooled studies — no. 11 5 5 8 5
* Plus–minus values are means ±SD. In the treatment group, there were significant differences in age group, sex, and percentage of partici-
pants living in institutions across the quartiles of actual intake of vitamin D. The range of actual intake of vitamin D in the highest quartile 
was unchanged when the one trial with a treatment dose of 2000 IU per day13 was excluded.
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ture (hazard ratio, 0.93; 95% CI, 0.87 to 0.99), 
with no risk reduction at doses of 400 IU per day 
or less (hazard ratio, 0.96; 95% CI, 0.89 to 1.05), 
and an 11% reduction at doses higher than 400 IU 
per day (hazard ratio, 0.89; 95% CI, 0.80 to 0.98). 
In the primary comparison of actual intake, the 
pattern was largely the same as that observed for 
hip fracture (Table 2). For prevention of nonver-
tebral fracture, a dose–response relationship was 
supported by the internal validation analysis (Ta-
ble 2) and by the threshold assessment of baseline 
25-hydroxyvitamin D level (Fig. 1B). Primary find-
ings at the highest actual-intake level were robust 
when individual trials were excluded (Appendixes 
2A and 2B in the Supplementary Appendix).
SENSITIVITY ANALYSES
When we included the trial-level findings for the 
two trials with missing source data8,9 (treatment 
doses, 800 IU and 833 IU per day) at the highest 
Table 2. Incidence of Fracture among 31,022 Participants, According to Vitamin D Treatment Dose and Actual Intake.*
Analysis
No. of  
Participants Hip Fracture Any Nonvertebral Fracture
No. of 
Fractures
Relative Risk
(95% CI) P Value
No. of 
Fractures
Relative Risk
(95% CI) P Value
Intention-to-treat analysis
Control 15,495 586 1.00 1948 1.00
Treatment 15,527 525 0.90 (0.80–1.01) 0.07 1822 0.93 (0.87–0.99) 0.03
Treatment-dose analysis
Control 15,495 586 1.00 1948 1.00
≤400 IU/day 10,111 255 0.89 (0.74–1.07) 0.20 1225 0.96 (0.89–1.05) 0.40
>400 IU/day† 5,416 270 0.91 (0.78–1.06) 0.22 597 0.89 (0.80–0.98) 0.02
Actual-intake analysis‡
Control 15,495 586 1.00 1948 1.00
0–360 IU/day 3,935 100 1.00 (0.79–1.26) 0.99 425 0.96 (0.86–1.07) 0.44
361–637 IU/day 3,836 110 1.03 (0.83–1.29) 0.78 520 1.01 (0.91–1.12) 0.85
638–791 IU/day 3,790 164 1.01 (0.83–1.23) 0.92 419 0.90 (0.80–1.01) 0.08
792–2000 IU/day 3,966 151 0.70 (0.58–0.86) <0.001 458 0.86 (0.76–0.96) 0.007
Sensitivity analysis
Control 15,495 586 1.00 1948 1.00
0–337 IU/day 3,353 84 1.01 (0.79–1.30) 0.91 465 1.06 (0.95–1.17) 0.32
338–360 IU/day 5,652 114 0.83 (0.66–1.05) 0.11 619 0.89 (0.80–0.98)§ 0.02
361–699 IU/day 2,640 180 1.14 (0.93–1.41) 0.21 326 1.05 (0.91–1.22) 0.52
700–2000 IU/day 3,882 147 0.71 (0.58–0.87) 0.001 412 0.81 (0.72–0.91) <0.001
Internal validation
0–360 IU/day 18,153 639 1.00 2193 1.00
361–637 IU/day 4,976 150 1.03 (0.84–1.26) 0.80 681 1.04 (0.95–1.15) 0.37
638–791 IU/day 3,865 168 1.02 (0.84–1.24) 0.83 431 0.92 (0.82–1.03) 0.16
792–2000 IU/day 4,028 154 0.70 (0.58–0.86) <0.001 465 0.86 (0.77–0.97) 0.01
* All analyses were adjusted for study, age group, sex, and type of dwelling. To limit false positive results and correct for multiplicity, we used 
a P value of 0.0125 to indicate significance.
† All trials included doses between 700 and 2000 IU per day.
‡ Among 21,241 participants from the eight trials that used vitamin D combined with any dose of calcium supplementation, a benefit was 
present only at the highest actual-intake level of vitamin D.
§ In the sensitivity analysis for adherence-adjusted dose without supplements outside the study protocol, 511 participants in the Women’s 
Health Initiative trial17 shifted from the highest actual-intake level (792 to 2000 IU per day) and 1356 shifted from the second-highest actual-
intake level (638 to 791 IU per day) to the second-lowest adherence-adjusted intake level (338 to 360 IU per day). See the Supplementary 
Appendix for additional information.
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actual-intake level, results were unchanged for 
hip fracture (relative risk, 0.70; 95% CI, 0.59 to 0.84) 
and any nonvertebral fracture (relative risk, 0.84; 
95% CI, 0.74 to 0.95). The inclusion of the trial by 
Sanders et al.,11 in which a high annual dose of 
vitamin D was administered, attenuated the find-
ings in the intention-to-treat analysis (Appendix 3 
in the Supplementary Appendix) and at the high-
est actual-intake level (Appendixes 2A and 2B in 
the Supplementary Appendix). The results of ad-
ditional sensitivity analyses were robust (data not 
shown), and there was homogeneity among trials 
at the quartile level of actual intake of vitamin D 
(Fig. 2A and 2B).
SUBGROUP ANALYSES
There were no significant interactions, after Bon-
ferroni adjustment, between the highest actual in-
take of vitamin D and subgroups defined by age, 
type of dwelling, baseline level of 25-hydroxyvita-
min D, and additional calcium intake (Table 3). 
This suggests that the effect of the highest actual 
intake of vitamin D was relatively consistent across 
these subgroups. However, reduced power, espe-
cially in the subset of participants for whom base-
line levels of 25-hydroxyvitamin D were available 
and the subset with additional calcium intake, may 
have masked some true differences. There was a 
suggestion that the highest actual-intake level of 
vitamin D was less beneficial for the prevention 
of nonvertebral fracture in participants living in 
community dwellings than in those living in in-
stitutions (P = 0.02), with the P value indicating a 
significant difference on the basis of the conven-
tional threshold for significance but not the Bon-
ferroni-adjusted threshold.
DISCUSSION
This pooled analysis included a large participant-
level data sample of double-blind, randomized, 
controlled trials of vitamin D supplementation that 
involved persons 65 years of age or older. The find-
ings suggest that only a high intake of vitamin D 
leads to a significant reduction in the risk of 
fracture — with a 30% reduction in the risk of hip 
fracture and a 14% reduction in the risk of any 
nonvertebral fracture; this reduction is indepen-
dent of the assigned treatment dose of vitamin D, 
age group, sex, type of dwelling, and study. Thus, 
it is possible that the results of typical intention-
to-treat analyses of vitamin D supplementation, 
as replicated in this pooled analysis with a non-
significant 10% reduction in the risk of hip frac-
ture and a 7% reduction in the risk of any nonver-
tebral fracture, underestimate the benefit of 
vitamin D supplementation. Notably, the benefit 
at the highest actual-intake level of vitamin D was 
confirmed in the internal validation analysis, 
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Figure 1. Threshold Assessment for the Risk of Fracture, 
According to Quartile of Baseline 25-Hydroxyvitamin D 
Level.
Panel A shows the risk of hip fracture, and Panel B the 
risk of any nonvertebral fracture. Among the 4383 study 
participants for whom data on baseline 25-hydroxyvita-
min D levels were available, there were 313 hip and 914 
nonvertebral fractures during follow-up. After adjustment 
for study, group assignment (treatment or control), age 
group, sex, and type of dwelling, persons 65 years of 
age or older with baseline serum 25-hydroxyvitamin D 
levels of at least 61 nmol per liter, as compared with 
persons with baseline levels of less than 30 nmol per 
liter, had a risk of hip fracture that was reduced by 37% 
(hazard ratio, 0.63; 95% CI, 0.46 to 0.87) and a risk of 
any nonvertebral fracture that was reduced by 31% 
(hazard ratio, 0.69; 95% CI, 0.57 to 0.84). With higher 
quartiles of baseline 25-hydroxyvitamin D levels, there 
was a significant trend toward lower risks of hip fracture 
(P = 0.02) and any nonvertebral fracture (P<0.001). The 
bars indicate 95% confidence intervals.
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which compared the highest actual-intake level 
with the lowest, regardless of study assignment 
(treatment or control). A dose–response relation-
ship between vitamin D and fracture risk is further 
supported by our analysis of baseline levels of 
25-hydroxyvitamin D and prospective fracture risk.
Our findings suggest that some previous high-
quality trials of vitamin D supplementation either 
showed no benefit owing to lower-than-intended 
doses of vitamin D or showed an unexpected ben-
efit owing to higher-than-intended doses. For ex-
ample, the RECORD trial by Grant et al.16 was 
designed with an intended dose of 800 IU per day, 
but the actual intake of vitamin D was lower, with 
a mean intake of 539 IU per day in the group that 
received vitamin D combined with calcium and 
613 IU per day in the group that received vitamin 
D alone. Conversely, the Women’s Health Initia-
tive trial by Jackson et al.17 was designed with an 
intended dose of 400 IU per day, but the actual 
intake of vitamin D and the proportion of partici-
pants in the highest intake range were higher, 
which may in part explain the reduced risk of 
fracture that was observed in the older partici-
pants in that trial.
Previous meta-analyses have suggested that the 
benefits of vitamin D may be limited to older per-
sons who live in institutions.4,6 Our subgroup 
analyses suggest that at the highest actual-intake 
level, the risk of hip fracture is reduced among all 
persons 65 years of age or older, whether they live 
in the community or in an institution. Our data 
further suggest that persons who are most vul-
nerable to vitamin D deficiency — those 85 years 
of age or older and those with very low baseline 
levels of 25-hydroxyvitamin D — benefit from 
vitamin D supplementation at least as much as 
others do. However, because of the reduced 
sample size and power, we are not able to deter-
mine whether this benefit is greater or simply 
equivalent.
Several previous meta-analyses suggested that 
the dose of vitamin D is irrelevant when vitamin 
D is combined with calcium.4-7 In contrast, our 
pooled subgroup analyses of the eight double-
blind, randomized, controlled trials that used vi-
tamin D combined with calcium indicate that with 
combined supplementation, the risk of fracture 
is reduced only at the highest actual-intake level 
of vitamin D. Furthermore, our data suggest that 
at the highest actual-intake level of vitamin D, 
a smaller amount of calcium supplementation 
(<1000 mg per day), as compared with a larger 
amount (≥1000 mg per day), may be more benefi-
cial in reducing the risk of fracture — a finding 
that is consonant with epidemiologic studies.23,24
Our sensitivity analysis suggests that the vita-
min D dosing interval may be relevant for reduc-
ing the risk of fracture. When we included in our 
sensitivity analysis the trial by Sanders et al.,11 
in which one annual dose of vitamin was admin-
istered, the risk reduction was attenuated. Simi-
larly, another study of annual supplementation 
with injectable vitamin D showed a null effect on 
the risk of fracture.25 In contrast, a trial from 
which the source data set could not be retrieved 
showed that a dose of 100,000 IU of vitamin D 
taken orally every 4 months was associated with a 
33% reduction in the risk of a first hip, wrist, or 
forearm fracture, suggesting that the 4-month dos-
ing interval is satisfactory.8 More frequent dosing 
(daily or weekly) in adequate amounts is supported 
by our analysis as a means of lowering the risk 
of both hip and nonvertebral fractures.
The strengths of our pooled analysis are the 
large sample, the assessment of fracture risk by 
actual intake of vitamin D, and the consistency of 
the primary findings and the internal validation 
study. The principal limitation of our analysis is 
the unavailability of source data for 2 of the 14 
qualifying trials8,9; however, inclusion of the 
trial-level data from these studies in a random-
effects meta-analysis did not alter our findings. 
A further limitation is that we could not assess 
the effect of the highest quartile of actual intake 
of vitamin D (792 to 1000 IU per day) without ad-
ditional calcium, because all trials that gave higher 
doses of vitamin D (≥800 IU per day with good 
adherence) also gave calcium. The threshold as-
sessment of fracture was limited because baseline 
levels of 25-hydroxyvitamin D were available for 
only a subset of participants and because the as-
says used to measure 25-hydroxyvitamin varied 
among the studies. However, after adjustment for 
this variation and all other covariates, the dose–
response relationship remained significant.
Our findings support the most recent recom-
mendation from the Institute of Medicine26 that 
persons 65 years of age or older receive 800 IU of 
vitamin D per day, but suggest that a 25-hydroxyvi-
tamin D level of more than 60 nmol per liter may 
be most beneficial for reducing the risk of frac-
tures. Furthermore, although our data did not al-
low us to determine whether the actual-intake 
level of a calcium supplement influenced the ef-
fect of vitamin D at the highest actual-intake 
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level, it would be important for future studies to 
consider the possibility that a calcium-supplement 
intake of 1000 mg per day or more, combined 
with high-dose vitamin D (≥800 IU per day) may 
be harmful. Calcium supplements without vita-
min D have been reported to increase the risk of 
hip fracture.27
In conclusion, our data suggest that high-dose 
vitamin D supplementation (≥800 IU per day) may 
reduce the risk of hip fracture in persons 65 years 
of age or older, independently of type of dwelling, 
age, and sex. Furthermore, our data support a 
25-hydroxyvitamin D level above 60 nmol per 
liter for the prevention of fractures.
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